Advertisement
Advertisement
U.S. markets open in 6 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8300+0.3400 (+9.74%)
At close: 03:41PM EDT
Advertisement
Sign in to post a message.
  • b
    bioking
    Analyst has a ~ $480 million valuation or around $80 per share on this unknown low float biotech

    Pipeline
    https://www.addextherapeutics.com/files/cache/5c7f9ce6567681d6991b811d7544272b_f342.png

    Analyst report
    https://www.addextherapeutics.com/files/8415/9522/1747/20200720_update_report_Addex_FINAL.pdf

    Based on our NPV based valuation, we believe that Addex remains substantially undervalued at
    the current share price of CHF 1.40. We believe the share price decrease of the last few months is
    unjustified and provides a substantial buying opportunity as we expect significant news flow in the
    coming months as the COVID-19 pandemic diminishes. The announcement of Janssen’s decision
    to advance ADX71149 into a Phase IIa study has a positive effect on the valuation, and we expect
    the start of both dipraglurant Phase IIb/III pivotal study and ADX71149 Phase IIa Epilepsy study to
    have a positive impact on the Addex share price. Using our valuation model and taking into
    account the future revenues from its late-stage clinical pipeline and its current partnerships with
    Indivior and Janssen, we have increased our valuation to CHF 425-460 million, or CHF 13.00-14.00
    per share.
    Bullish
  • M
    M
    Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
    Thu Jan 21 07:02:03 2021 EDT
    First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021
    Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.

    Pre Market Resistance at 18.20 - then there is little resistance upwards.
  • S
    S
    $ADXN ADXN.S.W TICKER CHF SWISS THIS IS THERE PHARMACEUTICAL STOCK ITS ROCKETING TODAY thats the ticker its there pharmaceutical side look at it already jumped 20%
  • P
    Paul R
    Nobody seems to care about this company. Under the radar is an understatement. I am accumulating. Join me for some fun. We can go to Switzerland for the next annual meeting. Beautiful place, I've been there. I see this as a takeover candidate because of their deep pipeline. If there are people that disagree, please post yoir opinion. I am always looking to reevaluate based on new info.
  • l
    luz
    This is my first operation in ADXN and I won... Now seem I have to pay taxes to take out the money. Can someone explain me if this is true?
    Bullish
  • P
    Paul R
    There are a whole lot of ADXN "catalysts" (I hate that word) either imminent or scheduled for Q2. Epilepsy, Parkinson's, twitchy eyelids (don't laugh, that can be a big problem). I think now is a good price and time to accumulate. This Swiss company is flying under the radar but not for much longer I believe.
  • H
    Hokiefun
    This company partnered years back with J and J and actually have very different pipeline. Suppose to be a read out soon.
  • D
    Denny
    Go Guys... One of the most shorted stock with low Float!
    Bullish
  • T
    Tim
    What part of the game is this? Got in at $15.50 and thought I was doing something. Feels like it’s being held down. Might have to wait for AH
  • K
    KingBoston!
    3 o’clock sour hour. Can it fill the gap?
    Bearish
  • J
    Jerry
    why no one buys this
  • H
    Hokiefun
    What moving this today? Was going to add to this but had it for the last few years in foreign shares.
  • R
    Reza
    absolutely undervalued because of the current situation in the market.
  • B
    Biotechinvestor
    Check out this youtube video that explains trading biotech stocks with decent strategies and explanations.

    I wish I watched this years ago, it would have save me a lot of time.

    Enjoy

    https://youtu.be/NPnKFYrib5Q
  • S
    S
    They have a breakthrough on parkinsonism disease trial is January 2021
  • P
    Paul R
    Seems like a good buy now after the recent drop due to the offering. Addex has a deep pipeline and now more $ (or actually CHF) to advance it.
    Bullish
  • K
    KingBoston!
    I’m pretty sure Darmesh shorted this when he told his minions to buy this morning
    Bearish
  • m
    mr
    Pre-market was $18.08 so buying anything below is a bonus
    Bullish
  • S
    S
    This is going to rock today
  • S
    S
    Parkinson breakthrough huge PR coming guys this is why this stock is moving
Advertisement
Advertisement